Список литературы к Главе 15

1. Petersen S.L. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning // Dan. Med. Bull. 2007. Vol. 54. P. 112–139.

2. Champlin R. et al. Allogeneic hematopoietic transplantation as adoptive immunotherapy induction of graft-versus-malignancy as primary therapy // Hematol. Oncol. Clin. 1999. Vol. 13. P. 1041–1053.

3. Schetelig J. et al. Evidence of a graft-versus-leukemia effect in chronic lymphocytic leukemia after reduced-intensity conditioning and allogeneic stem-cell transplantation: the cooperative German Transplant Study Group // J. Clin. Oncol. 2003. Vol. 21. P. 2747–2753.

4. Michallet M. et al. Allogeneic bone marrow transplantation in chronic lymphocytic leukemia: 17 cases. Report from the EBMTG // Bone Marrow Transplant. 1991. Vol. 7. P. 275–279.

5. Bandini G. et al. Bone marrow transplantation for chronic lymphocytic leukemia // Bone Marrow Transplantation. 1991. Vol. 7, N 4. P. 251–253.

6. Pavletic Z.P. et al. Bone marrow transplantation in chronic lymphocytic leukemia and lymphomas // Biomed. Pharmacother. 1996. Vol. 50. P. 118–124.

7. Khouri I., Giralt S., Champlin R. Non-myeloablative allogeneic hematopoietic transplantation and induction of graft-versus-malignancy // Cancer Treat. Res. 2002. Vol. 110. P. 137–147.

8. Slavin S. et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases // Blood. 1998. Vol. 91. P. 756–763.

9. Giralt S. et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy // Blood. 1997. Vol. 89. P. 4531–4536.

10. Gratwohl A. et al. The EBMT activity survey 2007 with focus on allogeneic HSCT for AML and novel cellular therapies // Bone Marrow Transplant. 2009. Vol. 43. P. 275–291.

11. Passweg J.R. et al. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T’s come into focus // Bone Marrow Transplant. 2020. Vol. 55. P. 1604–1613.

12. Khouri I.F. et al. BFR (bendamustine, fludarabine, and rituximab) allogeneic conditioning for chronic lymphocytic leukemia/lymphoma: reduced myelosuppression and GVHD // Blood. 2014. Vol. 124. P. 2306–2312.

13. Dreger P. et al. Indication for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus // Leukemia. 2007. Vol. 21. P. 12–17.

14. Rizouli V., Gribben J.G. Role of autologous stem cell transplantation in chronic lymphocytic leukemia // Curr. Opin. Hematol. 2003. Vol. 10. P. 306–311.

15. Reljic T. et al. High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia. A systemic review // Bone Marrow Transplant. 2015. Vol. 50. P. 1069–1074.

16. Rabinowe S.N. et al. Autologous and allogeic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia // Blood. 1993. Vol. 82. P. 1366–1376.

17. Dyer M.J. et al. In vivo purging of residual disease in CLL with Campath-1H // Br. J. Hematol. 1997. Vol. 97. P. 669–672.

18. Passweg J.R.; for the European Society for Blood and Marrow Transplantation (EBMT). The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies // Bone Marrow Transplant. 2019. Vol. 54. P. 1575–1585.

19. Dreger P. et al. High-risk chronic lymphocytic leukemia in the era of pathway inhibitors: integrating molecular and cellular therapies // Blood. 2018. Vol. 132. P. 892–902.

20. Schetelig J. et al. Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation // Bone Marrow Transplant. 2017. Vol. 52. P. 552–560.

21. O’Brien SM et al. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience // Blood. 2018. Vol. 131. P. 1910–1919.

22. Gribben J.G. How and when I do allogeneic transplant in CLL // Blood. 2018. Vol. 132. P. 31–39.

23. Brown J.R. et al. Predictors of improved progression-free survival after nonmyeloablative allogeneic stem cell transplantation for advanced chronic lymphocytic leukemia // Biol. Blood Marrow Transplant. 2006. Vol. 12. P. 1056–1064.

24. van Gelder M. et al. Baseline characteristics predicting very good outcome of allogeneic hematopoietic cell transplantation in young patients with high cytogenetic risk chronic lymphocytic leukemia – a retrospective analysis from the Chronic Malignancies Working Party of the EBMT // Clin. Lymphoma Myeloma Leuk. 2017. Vol. 17. P. 667–675.

25. Dreger P. Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties // Bone Marrow Transplant. 2019. Vol. 54, N 1. P. 44–52.

26. Roeker L.E. et al. Allogeneic stem cell transplantation (alloHSCT) for chronic lymphocytic leukemia (CLL) in the era of novel agents // Blood. 2019. Vol. 134, suppl. 1. P. 3321.

27. Dreger P. et al. TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial // Blood. 2013. Vol. 121. P. 3284–3288.

28. Roberts A.W. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia // N. Engl. J. Med. 2016. Vol. 374. P. 311–322.

29. Sorror M. et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT // Blood. 2005. Vol. 106. P. 2912–2919.

30. Raimondi R. et al. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index: a prospective, multicenter GITMO study // Blood. 2012. Vol. 120, N 6. P. 1327–1333.

31. Paul S. et al. Allogeneic haploidentical blood or marrow transplantation with post-transplantation cyclophosphamide in chronic lymphocytic leukemia // Biol. Blood Marrow Transplant. 2020. Vol. 26. P. 502–508.

32. Kim H. et al. Prognostic score and cytogenetic risk classification for chronic lymphocytic leukemia patients: center for international blood and marrow transplant research report // Clin. Cancer Res. 2019. Vol. 25. P. 5143–5155.

33. van Gorkom G. et al. Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT // Bone Marrow Transplant. 2018. Vol. 53, N 3. P. 255–263.

34. Karam E. et al. Who is a better donor for recipients of allogeneic hematopoietic cell transplantation: a young HLA-mismatched haploidentical relative or an older fully HLA-matched sibling or unrelated donor? // Biol. Blood Marrow Transplant. 2019. Vol. 25. P. 2054–2060.

35. Gyurkocza B., Sandmaier B. Cnditioning regimens for hematopoietic cell transplantation: one size does not fit all // Blood. 2014. Vol. 124. P. 344–353.

36. Shadman M. et al. Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience // Bone Marrow Transplant. 2020. Vol. 55. P. 172–181.

37. Kramer I. et al. Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial // Blood. 2017. Vol. 130. P. 1477–1480.

38. Rahmat L.T., Logan A.C. Ibrutinib for the treatment of patients with chronic graft-versus-host disease after failure of one or more lines of systemic therapy // Drugs Today (Barc.). 2018. Vol. 54. P. 305–313.

39. Pan Z. et al, Discovery of selective irreversible inhibitors for Bruton’s tyrosine kinase // ChemMedChem. 2007. Vol. 2. P. 58–61.

40. Flynn R. et al. Increased T follicular helper cells and germinal center B cells are required for cGVHD and bronchiolitis obliterans // Blood. 2014. Vol. 123. P. 3988–3998.

41. Dubovsky J.A. et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease // J. Clin. Invest. 2014. Vol. 124. P. 4867–4876.

42. Schutt S.D. et al. Inhibition of BTK and ITK with ibrutinib is effective in the prevention of chronic graft-versus-host disease in mice // PLoS One. 2015. Vol. 10. Article ID e0137641.

43. Miklos D. et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy // Blood. 2017. Vol. 130. P. 2243–2250.

44. Tensilk-Cross A. et al. Ibrutinib for the treatment of chronic graft versus host disease in pediatric patients // Biol. Blood Marrow Transplant. 2019. Vol. 25, N 3. P. S93–S94. Abstr. 125.

45. Waller E.K. et al. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy: 1-year update of a phase 1b/2 study // Biol. Blood Marrow Transplant. 2019. Vol. 25. P. 2002–2007.

46. Rozovski U. et al. Outcomes of patients with chronic lymphocytic leukemia and Richter’s transformation after transplantation failure // J. Clin. Oncol. 2015. Vol. 33. P. 1557–1563.

47. Mehta R.S. et al. Lenalidomide-induced graft-vs.-Leukemia effect in a patient with chronic lymphocytic leukemia who relapsed after allogeneic stem cell transplant // Clin. Lymphoma Myeloma Leuk. 2014. Vol. 14. P. e105–e109.

48. Hahn M. et al. Allogeneic hematopoietic stem cell transplantation for poor-risk chronic lymphocytic leukemia: dissecting immunemodulating strategies for disease eradication and treatment of relapse // Bone Marrow Transplant. 2015. Vol. 50. P. 1279–1285.

49. Inamoto Y. et al. A phase I/II study of chemotherapy followed by donor lymphocyte infusion plus interleukin-2 for relapsed acute leukemia after allogeneic hematopoietic cell transplantation // Biol. Blood Marrow Transplant. 2011. Vol. 17. P. 1308–1315.

50. Michallet M. et al. Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia // Bone Marrow Transplant. 2020. Vol. 55, N 5. P. 884–890.

51. Ryan C.E. et al. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT // Blood. 2016. Vol. 128, N 25. P. 2899–2908.

52. Niemann C.U. et al. Disruption of in vivo chronic lymphocytic leukemia tumor-microinvironment interactions by ibrutinib-findings from an investigator-initiated phase II study // Clin. Cancer Res. 2016. Vol. 22. P. 1572–1582.

53. Al-Sawaf O. et al. Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia // Haematologica. 2019. Vol. 104. P. e224–e226.

54. Gabriel S.S., Bon N., Chen J. et al. Distinctive expression of Bcl-2 factors in regulatory t cells determines a pharmacological target to induce immunological tolerance // Front. Immunol. 2016. Vol. 7. P. 73.

55. Lemal R., Tournilhac O. State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019 // J. Immunother. Cancer. 2019. Vol. 7. P. 202.

56. Liu J. Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies // J. Hematol. Oncol. 2017. Vol. 10. P. 35.